CompletedNot Applicable

Investigate eNAMPT in Multiple Myeloma Biology and Establish Its Role in Disease Progression

Italy26 participantsStarted 2019-08-12

Plain-language summary

Based on our previous observations, here the investigator plans to further investigate eNAMPT in MM biology and to establish its role in disease progression where EMT acquisition represents an hallmark of cancers. Results deriving from proposal would hopefully identify novel biological vulnerabilities of such malignancy and an innovative biomarker for disease progression monitoring as well.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Male and female patients over 18 years of age; * PB-derived serum samples collected in different disease phases (MGUS, SMM, NDMM and RRMM MM patients) * Sufficient CD138+ cells or RNA from CD138+ cells are available; * ≥ 2 years median survival data and treatment data is available (progression free and overall survival); * Bone marrow sample acquired prior to the initiation of the therapy of interest; * Patients have consented for use of their sample for research purposes.

What they're measuring

To strengthen preliminary data

Timeframe: 2 years

Potential marker of PD

Timeframe: 2 years

Analysis both MM cells and MM-BMSC compartment.

Timeframe: 2 years

To investigate eNAMPT role

Timeframe: 2 years

To determine the effects

Timeframe: 2 years

Trial details

NCT IDNCT04137523

SponsorUniversity of Turin, Italy

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2019-08-12

View on ClinicalTrials.gov More Multiple Myeloma trials